Crohn Disease Prognostic Panel

2001613
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive
Ordering Recommendation

Aid in the diagnosis and prognostication of Crohn disease.

Mnemonic
CROHN PAN
Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Performed

Tue

Reported

1-8 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum separator tube (SST).

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma, other body fluids, grossly icteric, heat-inactivated, grossly hemolyzed, severely lipemic, or contaminated specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
(avoid repeated freeze/thaw cycles)

Reference Interval
Test Number
 Components
 Reference Interval
  Saccharomyces cerevisiae Ab (gASCA), IgG
0-44 Units Negative
45-50 Units Equivocal
51 Units or greater Positive

  Laminaribioside Carbohydrate Ab ALCA IgG
0-54 Units Negative
55-60 Units Equivocal
61 Units or greater Positive

  Mannobioside Carbohydrate Ab (AMCA), IgG
0-89 Units Negative
90-100 Units Equivocal
101 Units or greater Positive

  Chitobioside Carbohydrate Ab (ACCA), IgA
0-79 Units Negative
80-90 Units Equivocal
91 Units or greater Positive

Interpretive Data

Anti-glycan serologic markers may serve as an aid in the diagnosis of Crohn disease (CD) and an indicator of disease prognosis. Anti-saccharomyces cerevisiae antibody (gASCA) has the highest diagnostic value and anti-chitobioside carbohydrate antibody (ACCA) has the highest association with more-aggressive disease. Both ACCA and gASCA are associated equally with the need for surgery. When found in combination, these markers have the best diagnostic potential. A combination of two or more of the four anti-glycan markers have a significant association with complications and the need for surgery than any single marker alone. A negative result does not rule out CD.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Analyte Specific Reagent (ASR)

Note
Hotline History
N/A
CPT Codes

86671; 83516 x3

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2001609 Saccharomyces cerevisiae Ab (gASCA), IgG 47321-5
2001610 Mannobioside Carbohydrate Ab (AMCA), IgG 53597-1
2001611 Laminaribioside Carbohydrate Ab ALCA IgG 53596-3
2001612 Chitobioside Carbohydrate Ab (ACCA), IgA 53594-8
2013334 Crohn Disease Prognostic Pan Interp. 62364-5
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chitobioside Carbohydrate Antibody (ACCA), IgA
  • Glycan Antibodies
  • IBD Prognostic Panel
  • IBDX
  • Inflammatory Bowel Disease Prognostic Panel
  • Laminaribioside Carbohydrate Antibody (ALCA), IgG
  • Saccharomyces cerevisiae Antibody (gASCA), IgG
Crohn Disease Prognostic Panel